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Abstract
Background: We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-
sectionally describe participant characteristics, and to evaluate the SCD-plus criteria.
Methods: The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants
undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission
tomography scan, with annual follow-up. The primary outcome measure is clinical progression.
Results: Cross-sectional evaluation of the first 151 participants (age 64 ± 8, 44% female, Mini-Mental State
Examination 29 ± 2) showed that 28 (25%) had preclinical Alzheimer’s disease (AD) (amyloid status available n = 114
(75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were
associated with worse objective performance. The SCD-plus criteria age ≥ 60 (OR 7.7 (95% CI 1.7–38.9)) and
apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6–15.0)) were associated with preclinical AD.
Conclusions: The SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and
subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD.
Further inclusion and follow-up will address important questions related to SCD.
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Background
Alzheimer’s disease (AD) develops gradually, and the
first pathophysiological changes occur decades before a
diagnosis of dementia [1, 2]. Research interest is shifting
to increasingly earlier stages, as the origin of AD and
keys to treatment probably lie in the prevention of pro-
gression to fully fledged disease. Preclinical AD is de-
fined as an asymptomatic stage of AD, in which AD
biomarkers are aberrant but clinical symptoms of object-
ive cognitive decline are not present [3]. Subjective cog-
nitive decline (SCD) refers to the experience of cognitive
decline, without formal deficits on neuropsychological
testing, or any other neurological or psychiatric diagno-
sis explaining cognitive complaints [4]. The subjective
experience of cognitive decline has been suggested to be
one of the first symptoms of AD, and patients with SCD
have an increased risk of progression to MCI or demen-
tia, especially when complaints are reported by both pa-
tient and informant [5–10]. In cognitively normal
individuals with SCD, biomarkers of AD can already be
aberrant, such as low CSF amyoid-beta1–42, increased
amyloid deposition on PET scans, and thinner medial
temporal cortex [11–14]. However, the sequence of neu-
rodegenerative changes eventually leading to AD may
vary amongst individuals, and where to place SCD in
these pathological sequences remains to be elucidated.
It is difficult to clinically identify preclinical AD in
cognitively healthy individuals experiencing memory
complaints. To increase the likelihood of preclinical AD
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in individuals with SCD, the SCD-I Working Group has
proposed the SCD-plus criteria [4]. These criteria in-
clude biomarkers such as APOE e4 carriership, but also
patient specific features such as predominant
self-perceived memory decline and feeling of worse
memory performance than others of the same age. The
SCD-plus criteria have been proposed to facilitate har-
monizing SCD research, but they have not yet been pro-
spectively validated.
Even though individuals with SCD on average have an
increased risk of AD, most individuals with SCD do not
harbor Alzheimer pathology. Alternative potential expla-
nations for the experience of memory complaints in
cognitive healthy individuals include subthreshold symp-
toms of affective disorders, personality features, lifestyle
factors, or systemic illnesses [15–17]. To evaluate the
contribution of different factors related to SCD we have
set up the memory clinic-based Subjective Cognitive Im-
pairment Cohort (SCIENCe). In this ongoing cohort
study we investigate individuals with SCD, without
major psychiatric of neurological disorders. Here, we
aimed to describe the SCIENCe study design, to
cross-sectionally evaluate participants characteristics and
factors related to cognitive complaints, and to evaluate
the recently defined SCD-plus criteria as indicators of
preclinical AD.
Methods
Study design and work-up
The Subjective Cognitive Impairment Cohort (SCIENCe)
is a prospective cohort study including consecutive pa-
tients with SCD presenting at the Alzheimer Center of
the VU University Medical Center Amsterdam. Here, we
extensively describe the study design of the ongoing
SCIENCe study. In addition, we report results based on
a selection of cross-sectional data of the first 151 SCI-
ENCe participants.
Inclusion criteria for the SCIENCe are a diagnosis of
SCD (i.e., cognitive complaints and normal cognition)
and age ≥ 45 years. Exclusion criteria are MCI, dementia,
major psychiatric disorder (i.e., current depression, per-
sonality disorders, schizophrenia), neurological diseases
known to cause memory complaints (i.e., Parkinson’s
disease, epilepsy), HIV, abuse of alcohol or other sub-
stances, and language barrier.
All participants have been referred to the memory
clinic by their general practitioner, and a neurologist or
geriatrician in the case of a second opinion for evalu-
ation of cognitive complaints. They receive standardized
dementia screening at the memory clinic, including an
interview with a neurologist, physical and neurological
examination, neuropsychological assessment, as well as
routine analyses of blood, CSF, and brain magnetic res-
onance imaging (MRI). After the standardized dementia
screening, diagnoses are made in a multidisciplinary
consensus meeting. Patients receive a label of SCD when
cognitive functioning is normal and when there is no
diagnosis of MCI, dementia, or any other disease known
to cause memory complaints [18]. When subtle symp-
toms of an underlying psychiatric diagnosis, such as de-
pression, are suspected, patients are evaluated by an
experienced psychiatrist to exclude possible formal psy-
chiatric diagnoses as the cause of cognitive complaints.
Eligible patients with SCD are invited to participate in
the SCIENCe. After inclusion in the SCIENCe, partici-
pants are invited for additional baseline assessments,
which are described in detail in the following. After
completion of baseline assessment, patients are invited
for an annual follow-up visit consisting of clinical evalu-
ation, extensive neuropsychological assessment, and
questionnaires. At each follow-up visit, diagnoses are
reevaluated under supervision of a neurologist. Main
outcome measures are clinical progression to MCI or
dementia and decline in cognitive functioning. If pa-
tients progress to MCI or dementia they are offered the
possibility to return to a routine memory clinic
follow-up. The SCIENCe work-up is visualized in Fig. 1.
The local medical ethics committee of the VU University
Medical Center approved the study and all patients pro-
vide written informed consent for the use of their clinical
data and biomaterial in research. All research is conducted
in accordance with the Helsinki Declaration of 1975.
SCIENCe inclusion started in June 2014. In the first 2
years, 243 consecutive individuals aged 45 years or older
received a diagnosis of SCD, of which 56 were not eli-
gible for participation and 36 individuals were not inter-
ested in participation (Fig. 2). This led to inclusion of
151 individuals in the SCIENCe until the start of data
analysis for the current report. In this cross-sectional re-
port of SCIENCE baseline findings, we evaluate these
first 151 participants. Further inclusion in the SCIENCe
and follow-up of participants is currently ongoing.
Questionnaires
Additional file 1: Table S1 provides a detailed overview
of the questionnaires used to evaluate SCD, mental
health, instrumental activities of daily living, and lifestyle
(i.e., dietary intake, and physical and cognitive activity).
Subjective cognitive decline
We use the Dutch translation of the Cognitive Change
Index—self (CCI-S) and Cognitive Change Index—in-
formant report (CCI-I) (20 questions, range 0–80) to as-
sess cognitive function compared to 5 years ago [13].
Higher scores reflect worse subjective cognitive function.
The CCI cutoff value for significant cognitive complaints
is set at 16/80 [19]. In addition, we use the Subjective
Cognitive Functioning (SCF) questionnaire (four
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questions, range − 12 to + 12) to assess self-experienced
cognitive decline over a 1-year time period [20]. A SCF
score below 0 represents decline.
Psychiatric symptoms
We use the following questionnaires to evaluate psychi-
atric symptoms: depressive symptoms, CES-D [21]; anx-
iety, HADS-A [22]; neuroticism, NPV neuroticism
subscale [23, 24], low mastery, Pearlin Mastery scale
[25]; distress and somatization (defined as nonspecific
physical complaints), 4-DKL distress and somatization
subscales [23]; and quality of life, EuroQol [26]. For all
psychiatric and quality-of-life questionnaires, higher
scores reflect worse performance. See Additional file 1:
Table S1 for cutoff values of the questionnaires.
Neuropsychological evaluation
All participants received a comprehensive standardized
neuropsychological assessment at the regular memory
clinic evaluation [18]. As part of the SCIENCe baseline
investigation we perform an additional neuropsycho-
logical assessment (median time between assessments
37 days) evaluating cognitive domains: memory, lan-
guage, attention, executive and visuospatial functioning,
with a special emphasis on memory; see Additional file
1: Table S1 for an overview of the complete SCIENCe
test battery. This test battery is repeated at follow up.
In this paper we report on a subset of the neuro-
psychological assessment. We used the MMSE to assess
global cognition [27]. For the memory domain we used
the Dutch version of the Rey Auditory Verbal Learning
Test (RAVLT)—direct recall (five trials summed) and de-
layed recall and cued recall (both > 20 min) [28]. We
used Trail Making Test (TMT) A to evaluate attention,
and TMT B to evaluate executive functioning [29]. To
evaluate language functioning we used categorical
animal fluency.
Magnetic resonance imaging
Structural MRI is acquired during the diagnostic visit to
the memory clinic using a MR750 (General Electric,
Milwaukee, WI, USA), Philips PET/MR (Philips Medical
Systems, Best, the Netherlands), or Toshiba Titan
(Toshiba Medical Systems, Otawara, Japan). The MRI
protocol includes isotropic 3D T1-weighted and Fluid
Attenuated Inversion Recovery (FLAIR) T2-weighted, and
Susceptibility Weighted Imaging (SWI). T1-weighted im-
ages are used to estimate hippocampal and normalized
brain volumes (NBV) using FIRST and SIENAX with opti-
mized settings (FMRIB software library v5, Oxford, UK)
[30, 31] derived from a tissue-type segmentation, using op-
timized parameter settings and a scaling factor to
normalize for skull size [31]. All registrations are visually
inspected for artifacts. All images are read by a neuroradi-
ologist in a standardized fashion. The severity of
Fig. 1 SCIENCe work-up. SCIENCe work-up at baseline and annual follow-up study visits. Primary outcome is clinical progression to MCI or
dementia. CSF cerebrospinal fluid, MCI mild cognitive impairment, MRI magnetic resonance imaging, PET positron emission tomography, SCIENCe
Subjective Cognitive Impairment Cohort
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white-matter hyperintensities (WMHs) using the
Fazekas scale is determined on the FLAIR sequence
(possible range 0–3), and dichotomized into absent
(0–1) or present (2–3). Lacunes are defined as deep
lesions (3–15 mm) with CSF-like signal on all
sequences. Lacunes are scored as absent or present
(≥ 1 lacune). Microbleeds are defined as small dot-like
hypointense lesions on T2-weighted MRI. Microbleed
count is dichotomized into absent or present (≥ 1 micro-
bleed). Here, we present baseline normalized brain vol-
ume, bilateral hippocampal volume, WMHs, lacunes, and
microbleeds. MRI data within 1 year from SCIENCe inclu-
sion were available for 116 (77%) participants.
Biomaterial for biobanking
Blood (serum and plasma), DNA, and CSF are obtained
and stored in our biobank at the department of Clinical
Chemistry of the VU University Medical Center
Amsterdam, according to international consensus stand-
ard operation procedures [32, 33].
Blood and DNA
Venous blood (2–6 ml clotted blood for serum and 6 ml
EDTA blood for plasma) is processed and stored accord-
ing to international consensus standard operation proce-
dures. EDTA whole blood (2–4 ml) is collected for DNA
extraction. After collection, plasma and serum samples
are centrifuged at room temperature at 2000 × g (mini-
mum 1800 × g, maximum 2200 × g), aliquoted into
0.5-ml vials, and stored at − 80 °C.
RNA
After SCIENCe inclusion, one PAXgene Blood RNA tube
(PreAnalytiX; Qiagen, Venlo, the Netherlands) is collected
and without aliquoting stored in the biobank at − 80 °C.
CSF
CSF is collected from nonfasted subjects. CSF is ob-
tained by lumbar puncture between the L3/L4 or L4/L5
intervertebral space by a 25-gauge needle and collected
in polypropylene tubes.
After collection, CSF and plasma samples are centri-
fuged at room temperature at 2000 × g (minimum
1800 × g, maximum 2200 × g), aliquotted into 0.5-ml
vials, and stored at − 80 °C. A maximum of 2 h is
allowed between collection and freezing [32, 33].
APOE genotyping
APOE genotyping is performed after automated genomic
DNA isolation from 2–4 ml EDTA blood. It is subjected
to PCR, checked for size and quantity using a QIAxcel
DNA Fast Analysis kit (Qiagen), and sequenced using
Sanger sequencing on an ABI130XL. Here, APOE status
was available for 144 (95%) individuals. Subjects with
one or two ε4 alleles were classified as APOE e4 carriers.
Cerebrospinal fluid markers
From the total amount of collected CSF at memory
clinic visit, 2.5 ml is used for routine analyses, including
leukocyte count, erythrocyte count, glucose concentra-
tion, and total amount of protein, and frozen at − 20 °C
Fig. 2 Flow chart of study inclusion. Flow-chart of inclusion of SCIENCe participants evaluated in current report (n = 151). Further inclusion and
follow-up currently ongoing. SCD subjective cognitive decline, SCIENCe Subjective Cognitive Impairment Cohort
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until further analysis of Alzheimer biomarkers.
Amyloid-beta1–42 (Aβ42), tau, and tau phosphorylated
threonine 181 (ptau) levels are measured using ELISA
(Innogenetics-Fujirebio, Ghent, Belgium) at the Neuro-
chemistry Laboratory [34]. Our center cutoff value for
CSF Aβ42 indicating AD pathology is < 640 μg/L [35].
Positron emission tomography scans
All participants are invited to participate additionally in an
amyloid PET study. Patients are scanned with either
[18F]florbetapir (Amyvid) or [18F]florbetaben (Neuraceg)
radiotracer. Before scanning, one cannula is inserted for
tracer infusion. For florbetapir, 90-min dynamic PET emis-
sion scans (PET/CT Ingenuity TF or Gemini TF; Philips
Medical Systems) are acquired immediately following
bolus injection of approximately 370 MBq [18F]florbetapir.
For florbetaben, 20-min static PET emission scans (PET/
MR; Philips Medical Systems) are acquired 90 min after a
bolus injection of approximately 250 MBq [18F]florbeta-
ben. All PET scans are visually read by a nuclear medicine
physician. For the current manuscript, PET scans were
available for 105/151 (69%) participants.
Amyloid status
Information on amyloid status was available for 114 (75%)
participants (PET only n = 38 (25% of total), CSF only n =
9 (6%), CSF and PET n = 67 (44%)). Amyloid status could
be determined if: CSF and/or amyloid PET was performed
within 1 year of baseline visit; or if repeated amyloid mea-
surements were concordant before and after baseline (i.e.,
both negative or both positive). There were seven cases
with discordant PET/CSF results. In all seven cases, CSF
Aβ42 was above the cutoff value of 640 μg/L (range 645–
881 μg/L), but amyloid PET was positive; we considered
these cases as amyloid positive.
Categorization of participants according to concomitant
symptoms
In this cross-sectional report of SCIENCE baseline find-
ings, we categorized SCIENCe participants into categor-
ies based on the presence of preclinical AD and/or
subthreshold psychiatry, as potential factors associated
with SCD [4].
Preclinical AD
Amyloid-positive individuals based on PET and/or CSF
amyloid (see Amyloid status) were classified as preclin-
ical AD.
Subthreshold psychiatry
Individuals with one or more questionnaires indicative
of subthreshold symptoms of depression, anxiety, neur-
oticism, low mastery, distress, or somatization were clas-
sified as subthreshold psychiatry (see Additional file 1:
Table S1 for an overview of questionnaires and cutoff
values used). Fulfillment of clinical criteria for a formal
psychiatric diagnosis was an exclusion criterion for the
SCIENCe, hence psychiatric symptoms measured with
the questionnaires were subthreshold. When participants
were amyloid positive but also had subthreshold psychi-
atric symptoms they were classified in the preclinical
AD group. Amyloid status was not available in the sub-
threshold psychiatry category for 21 of 58 cases (36%).
Undetermined
When participants were neither amyloid positive or
there was no indication of subthreshold psychiatric
symptoms, they were classified in the undetermined cat-
egory. Amyloid status was not available in the undeter-
mined category for 16 of 65 patients (25%).
SCD-plus criteria
The SCD-plus criteria refer to specific features of SCD as-
sociated with an increased likelihood of preclinical AD [4].
The SCD-plus criteria are: (1) subjective decline in mem-
ory, rather than other domains of cognition (in our study
defined as ‘memory decline present’ as evaluated in the
SCF questionnaire); (2) onset of SCD within the last 5 years;
(3) age at onset of SCD ≥ 60 years; (4) concerns (worries)
associated with SCD; (5) feeling of worse performance than
peers (here operationalized with a specific question in the
CCI questionnaire); (6) confirmation of perceived cognitive
decline by an informant (here operationalized as a CCI in-
formant report score above cutoff value of significant
symptoms (> 16)); and (7) APOE e4 carriership. We evalu-
ated the SCD-plus criteria with the exception of criterion
worries associated with SCD (4), which we considered
present in all participants since they all visited our mem-
ory clinic because of cognitive complaints.
Statistical analyses
Data were analyzed using IBM SPSS Statistics, version
22 (IBM, Armonk, NY, USA). We assessed baseline
features of the study population and evaluated differ-
ences between participant categories (preclinical AD,
subthreshold psychiatry, or undetermined), using
chi-squared tests or ANOVA, adjusted for age and gen-
der, as appropriate, followed by post-hoc analyses. We
used univariate linear regression analyses to assess asso-
ciations between cognitive complaints (CCI-S, CCI-I,
and SCF) and neuropsychological test scores, adjusted
for age and gender.
Furthermore, we evaluated the prevalence of the
SCD-plus criteria in participants with available amyl-
oid status. Subsequently, we used logistic regression
to investigate the associations of SCD-plus criteria
with the risk of preclinical AD. First, we performed
univariate models with each SCD-plus criterion
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separately (model 1). Then, we constructed model 2
as a multivariate model with backward stepwise selec-
tion with the six available SCD-plus criteria. We con-
sidered p < 0.05 significant.
Results
Baseline demographics
At baseline the first 151 SCIENCe participants were on
average 64 ± 8 years old (range 45–84 years), and 67 (44%)
were female (Table 1). Participants received on average 12
± 3 years of education, and 76 (54%) had a family history
of dementia. Fifty-five participants (38%) were APOE e4
positive (APOE e4 status available for n = 144 (95%)).
Self-report of SCD
We cross-sectionally assessed report of subjective cogni-
tive functioning compared to 1 year ago (SCF self-report)
and 5 years ago (CCI; both self-report and informant re-
port; Table 1). Over the preceding 5-year time period 146
(97%) participants reported cognitive decline (CCI-S), of
which 89 (60%) reported substantial decline. Over a 1-year
time period (SCF), 104 (69%) participants reported sub-
stantial cognitive decline. Adjusted for age, gender, and
education, higher CCI-S was associated with worse SCF
(standardized β = − 0.40, p < 0.001), and CCI-S was also
associated with CCI-I (sβ = 0.48, p < 0.001; Table 2). In
addition, we found that higher self-report of subjective
cognitive functioning (CCI-S and SCF) was associated with
worse quality of life (sβ = − 0.34; sβ = 0.25; both p < 0.05).
Furthermore, higher CCI (both self and informant) were
associated with worse performance on cognitive tests
(Table 2), while there were no associations between SCF
and objective measures of cognition.
SCD groups
When we attempted to categorize participants according
to the presence of preclinical AD and/or subthreshold
psychiatric symptoms, we found 28 individuals (25% of
114 participants with known amyloid status, and 18% of
total sample) with preclinical AD. Higher age was associ-
ated with an increased risk of preclinical AD (odds ratio
1.14 (95% CI 1.06–1.22); Fig. 3).
In the remaining sample, 58 (38%) participants re-
ported subthreshold psychiatric symptoms on one or
more questionnaires. Of these participants, 21% had sub-
threshold symptoms in the affective cluster, for example
depressive (11%) and/or anxiety (13%) symptoms. Roughly
one out of three (31%) had distress and/or
somatization-related symptoms, and in 27% there was an
indication of symptoms of neuroticism and/or low mas-
tery. In addition, 8 of 28 (29%) patients in the preclinical
AD category also had subthreshold psychiatric symptoms.
The largest group of SCD (n = 65 (43%)) had neither
evidence of amyloid nor of subthreshold psychiatric
symptoms (undetermined category).
Comparing these three SCD groups, participants with
preclinical AD were on average older than individuals in
the subthreshold psychiatry (p < 0.001; Table 1) and un-
determined category (p < 0.05). Participants with preclin-
ical AD more frequently had a family history of
dementia than subthreshold psychiatry, and they were
APOE e4 carriers more frequently than the other two
groups (all p < 0.01). There were no differences in gen-
der, education, or MRI measures between groups.
Self-reported cognitive decline was higher in participants
with subthreshold psychiatry than in the undetermined
category, with preclinical AD in between (both p < 0.01).
Results were similar for informant-reported cognitive
decline. Reported quality of life was lower in the sub-
threshold psychiatry group than in the undetermined
category (p = 0.002), with preclinical AD in between.
Comparing objective cognitive performance between
groups, the group with subthreshold psychiatry per-
formed worse on the TMT-A compared to preclinical
AD and undetermined groups (all p < 0.05). Also, sub-
threshold psychiatry performed worse on the TMT-B
than the undetermined group (p < 0.05), but there were
no differences in other cognitive tests, see Table 1.
SCD-plus criteria and the risk of preclinical AD
Univariate logistic regression analyses showed that
SCD-plus criteria ‘age ≥ 60’ (OR 7.7 (95% CI 1.7–34.6))
and ‘APOE e4 carriership’ (OR 5.0 (2.0–12.8)) were asso-
ciated with an increased risk of preclinical AD (Fig. 4),
whereas ‘memory specific decline’, ‘onset of complaints
within 5 years’, ‘worse performance than other of the
same age’, and ‘informant reports decline’ were not
(Table 3). In a multivariate stepwise model, APOE e4
carriership (OR 6.2 (1.7–22.2)) and age ≥ 60 (OR 3.8
(1.7–20.4)) remained independently associated with pre-
clinical AD.
Discussion
The SCIENCe project aims to investigate factors poten-
tially related to SCD. Cross-sectional evaluation of the
first 151 cognitively normal participants with SCD re-
vealed a heterogeneous group, with preclinical AD in
one fifth to one quarter of participants, and subthreshold
psychiatric symptoms in more than one third of partici-
pants, while the largest group of participants did not
have evidence of either. We found that higher report of
SCD was associated with lower quality of life, and also
with worse cognitive performance. Finally, the SCD-plus
criteria age ≥ 60 and APOE e4 carriership were associ-
ated with an increased risk of preclinical AD, defined by
amyloid positivity on either PET or in CSF.
Slot et al. Alzheimer's Research & Therapy  (2018) 10:76 Page 6 of 13
We measured the degree of subjective complaints with
the short SCF questionnaire and used the CCI for more
in-depth evaluation [13, 20]. Almost all participants re-
ported cognitive decline, which seems substantially
higher than in the general population [36], and could be
a reflection of our cohort with individuals actively
seeking medical evaluation in a memory clinic because
of these cognitive complaints. A small minority of 3%
did not report any complaints, potentially explained by
the fact that participants filled in the questionnaires after
a thorough memory clinic evaluation, with reassurance
of normal cognitive functioning.
Table 1 Demographic features of the study population
n Total group
(N = 151)
Preclinical AD
(n = 28)
Subthreshold
psychiatry (n = 58)
Undetermined
(n = 65)
p
Demographics Age 151 64 ± 8 69 ± 7b 62 ± 8a 64 ± 8a 0.002
Gender, female 151 67 (44) 11 (39) 27 (47) 29 (45) NS
Education (years) 148 12 ± 3 13 ± 3 12 ± 3 12 ± 2 NS
Family history dementia 140 76 (54) 18 (75)b 20 (36)a 38 (62)b 0.002
APOE e4 carrier 144 55 (38) 17 (65)b 17 (30)a 21 (34)a 0.007
n above
cutoff value
Subjective cognitive
decline
SCF (1-year change) self-
report
150 −1.65 ± 2.98 104 (69) −2.0 ± 2.3 −2.4 ± 3.2 −0.8 ± 2.9b 0.004
CCI (5-year change) self-
reportc
148 21.8 ± 14.3 89 (60) 21.4 ± 13.2b 27.8 ± 15.2a 16.7 ± 11.8b 0.000
CCI (5-year change)
informantc
127 19.4 ± 17.1 62 (49) 19.8 ± 13.9b 26.4 ± 19.1a 13.8 ± 14.8b 0.000
Mental health
questionnaires
Quality of Life 149 76 ± 15 79 ± 12 71 ± 16 80 ± 15b 0.012
Depressive symptomsc 150 8.3 ± 6.4 17 (11) 7.0 ± 4.6 12.1 ± 7.3 5.5 ± 4.1 0.000
Anxietyc 150 4.0 ± 2.9 13 (13) 4.1 ± 2.6 5.6 ± 3.1 2.4 ± 1.9 0.000
Distressc 150 6.7 ± 5.9 34 (22) 4.6 ± 4.6 11.1 ± 6.3 3.6 ± 2.9 0.000
Somatizationc 151 6.3 ± 5.3 31 (21) 4.6 ± 3.7 10.3 ± 5.7 3.5 ± 2.8 0.000
Neuroticismc 145 6.6 ± 5.5 5.2 ± 3.8 10.1 ± 6.4 4.0 ± 2.8 0.000
Low masteryc 140 10.5 ± 3.9 10.0 ± 3.0 12.8 ± 4.0 8.5 ± 2.7 0.000
Cognition MMSE 151 28.6 ± 1.2 28.4 ± 1.3 28.5 ± 1.2 28.9 ± 1.2 0.031
Memory domain RAVLT immediate recall 149 44.3 ± 9.0 43.4 ± 8.7 44.0 ± 9.0 44.6 ± 9.2 NS
RAVLT delayed recall 149 9.0 ± 2.9 8.5 ± 2.9 9.1 ± 3.0 9.2 ± 2.9 NS
RAVLT cued recall 149 28.7 ± 1.6 28.7 ± 1.5 28.5 ± 2.3 28.8 ± 1.4 NS
Attention TMT Ac 148 34.4 ± 12.8 33.4 ± 12.2b 37.5 ± 14.9a 32.1 ± 10.5b 0.014
Executive
functioning
TMT Bc 147 82.1 ± 33.2 79.5 ± 28.9 89.8 ± 41.0 76.2 ± 25.8b 0.058
Language Animal fluency 147 23.2 ± 5.2 22.8 ± 4.9 23.1 ± 5.1 23.5 ± 5.6 NS
MRI Normalized brain volume
(ml)
116 1399 ± 79 1366 ± 75 1407 ± 81 1406 ± 79 NS
Bilateral hippocampal
volume (ml)
116 9.9 ± 1.3 10.0 ± 1.4 9.9 ± 1.3 9.8 ± 1.1 NS
White-matter
hyperintensities (present)
116 10 (9) 2 (9) 2 (4) 6 (13) NS
Lacunes (> 0) 115 3 (3) 1 (4) 2 (5) 0 (0) NS
Microbleeds present (> 0) 112 19 (17) 7 (30) 4 (10) 8 (17) NS
Unadjusted results presented as mean ± standard deviation or n (%). Differences between groups assessed using age, gender, and education-adjusted analysis of
variance or chi-squared tests
AD Alzheimer’s disease, APOE apolipoprotein E genotype, CCI cognitive change index, MMSE Mini-Mental State Examination, MRI magnetic resonance imaging,
NS not significant, RAVLT Rey Auditory Verbal Learning Test, SCF subjective cognitive functioning, TMT Trail Making Test
ap < 0.05 difference with preclinical AD
bp < 0.05 difference with subthreshold psychiatry
cHigher scores reflect worse performance or more symptoms
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We found that higher report of cognitive complaints
was associated with worse quality of life, suggesting that
subjective complaints have a negative effect on a general
feeling of wellbeing. On the other hand, we cannot ex-
clude reverse causality, as worse quality of life may also
affect the subjective appreciation of one’s (cognitive)
abilities [37]. Furthermore, we found that higher report
of cognitive complaints on the CCI (both self and in-
formant) was associated with worse objective cognitive
performance in our cognitive normal sample with SCD,
which is in line with the literature on the CCI and ob-
jective performance [38]. Although self-report of SCD
has been associated with future cognitive decline [5, 8],
and also has been suggested to be more sensitive for
subtle decline than informant report in the very earliest
stages of cognitive decline, earlier cross-sectional associ-
ations have not been consistent [11, 39–41]. This could
be a result of the use of different SCD measures [42]. In-
deed, we found no significant associations between ob-
jective cognition and SCF, which measures cognitive
complaints over a shorter period of time and consists of
four questions only, in contrast to the observed associa-
tions with the CCI.
Cognitive complaints in cognitively normal individuals
were previously found to have a broad range of associated
symptoms, varying from distress to affective disorders, sys-
temic illnesses, and preclinical AD [11, 12, 15, 16, 39]. In
the current paper we evaluated the prevalence of preclin-
ical AD and subthreshold psychiatric features as potential
factors associated with the occurrence of SCD [4]. We ob-
served that 25% of participants with available amyloid sta-
tus had preclinical AD, and amyloid positivity increased
with age. Although we did not make a formal comparison,
percentages of amyloid positivity per decade seem some-
what higher in our cohort than in individuals with SCD in
a recent large meta-analysis investigating amyloid preva-
lence in the nondemented elderly [43].
In our sample, 38% of participants experienced
subthreshold psychiatric symptoms on one or more do-
mains. These symptoms were labeled subthreshold
since individuals with a clear psychiatric diagnosis,
such as major depression, were not included. The
group with subthreshold psychiatric symptoms re-
ported more cognitive complaints than the group with
preclinical AD. We evaluated six psychiatric features
which have been previously associated with cognitive
complaints in individuals with SCD, and might provide
an alternative explanation for the subjective experience
of decline [15, 16, 39, 41, 44]. On the other hand, sev-
eral of these psychiatric features, such as depressive
symptoms, anxiety, neuroticism, and distress, have also
been associated with preclinical AD [45–51], and, in-
deed, we also saw the co-occurrence of preclinical AD
and subthreshold psychiatric symptoms in 8 of 28
cases. We are currently following all participants to
study clinical progression in these different groups.
For 43% of the remaining SCIENCe participants, we
found neither preclinical AD nor subthreshold psych-
iatry. Individuals in the undetermined category had
fewer cognitive complaints than the other two categor-
ies, both reported by themselves and by the informant.
Nonetheless, each of these patients was referred to the
memory clinic for evaluation of complaints. In the un-
determined category we found a higher prevalence of
Table 2 Associations between subjective and objective
cognitive measures
SCF CCI-self CCI-informant
CCI-selfa − 0.39**
CCI-informanta − 0.19* 0.49**
EuroQol 0.25* − 0.33** − 0.15
MMSE 0.14 − 0.30** − 0.10
RAVLT immediate recall 0.01 − 0.21* − 0.15
RAVLT delayed recall 0.03 − 0.16 − 0.04
RAVLT cued recall − 0.12 − 0.23* − 0.17*
TMT Aa − 0.06 0.12 0.17
TMT Ba − 0.17 0.23* 0.26*
Animal fluency 0.15 − 0.15 − 0.14
Associations presented as standardized β, adjusted for age, gender, and education
SCF subjective cognitive functioning (lower scores indicate more complaints),
CCI cognitive change index (higher scores indicate more complaints), MMSE
Mini-Mental State Examination, RAVLT Rey Auditory Verbal Learning Test,
TMT Trail Making Test
*p < 0.05
**p < 0.001
aHigher scores reflect worse cognitive performance
Fig. 3 Percentage of amyloid positivity per decade. Percentage of
amyloid positivity per age category in participants with available
amyloid status (n = 114)
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family history of dementia than in the subthreshold
psychiatry category, similar to preclinical AD. Perhaps
anxiousness related to family history of dementia,
rather than the actual experience of cognitive decline,
could be a reason to visit the memory clinic for
evaluation [52].
To facilitate harmonization of SCD research, the inter-
national SCD Working Group (SCD-I) has published a
conceptual framework on SCD research, which included
the SCD-plus criteria as determinants of preclinical AD
[4]. This is the first time the SCD-plus criteria were com-
prehensively evaluated in a clinical setting. We found that
the SCD-plus criteria age ≥ 60 and APOE e4 carriership
were associated with an increased risk of preclinical AD,
which is in line with the literature [11, 43, 53]. The four
other SCD-plus criteria we evaluated were not associated
with preclinical AD in our cohort. There was a trend for
an increased risk of preclinical AD when the informant re-
ported significant decline, but results were not significant.
The lack of association between informant report and pre-
clinical AD is in contrast with a previous study showing
an association between these factors [54]. This contrast
could possibly be explained by differences in informant re-
port measurement methods, as well as differences in sam-
ple size between the previous study and ours. Since
informant report seems to be a better predictor of future
cognitive decline than patient report [7, 10, 55], future lon-
gitudinal evaluation of SCIENCe participants and
Fig. 4 SCD-plus criteria and risk of preclinical AD. Risk of preclinical AD for each SCD-plus criterion in participants with available amyloid status
(n = 114). AD Alzheimer’s disease, APOE apolipoprotein E (genotype), CI confidence interval, OR odds ratio
Table 3 SCD-plus criteria and the risk of preclinical AD in individuals with available amyloid status (n = 114)
Predictor Data availability (n) Prevalence of SCD-plus criteriaa Risk of preclinical ADb
in group with known
amyloid status (n = 114)
Preclinical AD
(n = 28)
Amyloid negative
(n = 86)
Univariate model Multivariate
stepwise model
Memory specific decline 94 13 (59%) 37 (51%) 1.4 (0.5–3.6) –
Onset < 5 years 111 12 (46%) 43 (51%) 0.8 (0.3–2.0) –
Age ≥ 60 years 114 26 (93%) 54 (63%) 7.7 (1.7–34.6) 3.8 (1.7–20.4)
Experience of worse performance than others 90 13 (65%) 44 (63%) 1.1 (0.4–3.1) –
Informant reports decline 97 15 (60%) 32 (44%) 1.9 (0.7–4.7) –
APOE e4 carriership 110 17 (65%) 23 (27%) 5.0 (2.0–12.8) 6.2 (1.7–22.2)
AD Alzheimer’s disease, APOE apolipoprotein E (genotype), SCD subjective cognitive decline
aPrevalence of each SCD-plus criterion in individuals with and without preclinical AD, presented as n (%), within cases with amyloid status available (n = 114)
bRisk of preclinical AD separately (univariate models) for each SCD-plus criterion and independent predictors of preclinical AD in a multivariate stepwise model in
SCIENCe participants with available amyloid status (n = 114), presented as odds ratio (95% confidence interval)
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extension of sample size may reveal further relations. Fur-
thermore, the criteria ‘worse performance than others of
the same age’ and ‘memory specific decline’ were not asso-
ciated with an increased risk of preclinical AD, which is in
contrast to previous studies indicating both concepts to be
associated with preclinical AD [11, 56]. We used questions
from the CCI and SCF to assess these topics (respectively
feeling of worse performance than others (yes/no) and how
do you evaluate your memory function compared to 1 year
ago (stable/decline)). For these two SCD-plus criteria, dif-
ferences between results may be caused by methodological
variation in SCD measurements, which are known to re-
sult in great variation between studies [42]. Criterion ‘on-
set of symptoms within 5 years’ did not alter the risk of
preclinical AD in our cohort. To our knowledge this is the
first study evaluating the association between onset of
symptoms within 5 years and preclinical AD, whereas
others evaluated the risk of future cognitive decline in re-
lation to onset of symptoms, without taking into account
preclinical AD [57–59].
Limitations of the study include the availability of
amyloid status in the cohort for 114 of 151 participants.
Because of the availability of amyloid status, participants
that are now classified in the subthreshold or undeter-
mined category may have preclinical AD of which we
are unaware, since we hierarchically first included partic-
ipants in the preclinical AD group, followed by
categorization of the remaining participants (amyloid
status negative or unknown) in the other two groups.
Strengths of the study include the highly standardized
assessment of a broad range of factors potentially related
to SCD, including various biomarkers, as well as re-
peated collection of blood and CSF for biobanking to be
able to evaluate biomarkers longitudinally.
In the light of a disease evolving over decades, longi-
tudinal evaluation seems necessary to assess if, and
when, those with and without preclinical AD eventually
show progression to MCI or dementia. In SCIENCe we
aim to evaluate which factors predict progression, but
also which factors are protective of future decline.
Discriminating preclinical AD from the ‘worried well’
seems especially important as anti-amyloid therapies
targeting early stages of AD appear a realistic possibility
in the nearby future [60]. Furthermore, assessment of
factors other than preclinical AD contributing to SCD
may be of importance, since also nonpharmacological
interventions seem to be of added value in individuals
with SCD [61].
Conclusions
In summary, this first cross-sectional evaluation of SCI-
ENCe participants revealed that SCD is a heterogeneous
group, with subthreshold psychiatric features alongside
preclinical AD. We found that subjective report of decline
was associated with objective measures. Furthermore, we
found a number of SCD-plus criteria to be associated with
preclinical AD. Further inclusion and follow-up will ad-
dress important questions related to SCD.
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